cMYC degrader therapeutic - InSilico Medicine
Latest Information Update: 07 Sep 2023
At a glance
- Originator InSilico Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myc degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 21 Aug 2023 Insilico Medicine plans an IND-enabling study for Solid tumours in 2024
- 14 Aug 2023 Early research in Solid tumours in USA (unspecified route) prior to August 2023 (InSilico Medicine Pipeline, August 2023)
- 14 Aug 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by Insilico Medicine (before August 2023)